{
    "symbol": "BCAB",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-07 15:06:04",
    "content": " When you see the type of response we're seeing in osteosarcoma in terms of PFS at three months of 67%, that is highly encouraging for us to move into a Phase 2 study, in light of the fact that these patients were advanced patients, they had on average three prior lines of therapy, with patients that are metastatic and have one to two prior lines of treatment studies have shown that these patients generally progress within 8 weeks."
}